Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups Meeting Abstract
| Authors: | Mora, J.; Chan, G. C. F.; Morgenstern, D. A.; Nysom, K.; Bear, M.; Tornøe, K.; Sørensen, P. S.; Kushner, B. H. |
| Abstract Title: | Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HRNB): Response data and efficacy in patient (pt) subgroups |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304507 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.e22019 |
| Notes: | Meeting Abstract: e22019 -- Meeting also held virtually -- Source: Wos |
